Heart Evaluation of Acute Ischemic Stroke With Reperfusion Therapy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Rate of Major Adverse Cardiovascular Events
Study Overview
Brief Summary
Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy (HEART) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy.
This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
Detailed Description
There is growing evidence pointing to close interactions between acute ischemic stroke (AIS) and heart diseases. Heart diseases may lead to AIS (heart-to-brain interactions), with many cardiac conditions have been proposed as potential sources of cerebral embolism, and studies have also shown that AIS can induce cardiac injury (brain-to-heart interactions), namely Stroke-Heart Syndrome. In addition, due to the commonly shared risk factors, AIS patients had a significantly higher frequency of coexisting prior known or unknown coronary heart disease (brain-and-heart interactions). These heart problems not only add complexity to the etiological diagnosis but also account for a great proportionate mortality in AIS patients with reperfusion therapy, which is the most effective treatment method for AIS. The interconnected and coexisting properties of AIS and heart diseases requires a comprehensive scheme to evaluate, prevent, and treat patients.
Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy (HEART) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy.
This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
The clinical, laboratory and imaging information will be collected at the baseline. During an estimated 3-year follow-up, the diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent by patient
- •Age ≥ 18 years
- •Acute ischemic stroke (with matching brain lesion on MR imaging)
- •Enrolment within 24 h after onset of stroke-related symptoms.
Exclusion Criteria
- •Pregnancy and / or breast-feeding.
- •Participation in an interventional study.
- •Patients refuse to participate in the research.
Outcomes
Primary Outcomes
Rate of Major Adverse Cardiovascular Events
Time Frame: 1 year
cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina
Secondary Outcomes
- Rate of Ischemic Stroke(3 years)
- Rate of Cardiovascular Mortality(3 years)
- Rate of Major Adverse Cardiovascular Events(3 years)
- Functional Outcome(90 days)
- Rate of Acute Coronary Syndrome(3 years)
- Time to First Major Adverse Cardiovascular Event(3 years)
- Time to First Ischemic Stroke(3 years)
Investigators
Jianqiang Ni
Clinical Professor
The First Affiliated Hospital of Soochow University